Hal Barron, GSK Investor Day

Glax­o­SmithK­line punts a key Ze­ju­la com­bo study in ovar­i­an can­cer with added set­backs on ICOS and RSV

A chink has ap­peared in the ar­mor of da­ta that Glax­o­SmithK­line R&D chief Hal Bar­ron has been build­ing for the PARP in­hibitor Ze­ju­la.

The phar­ma gi­ant’s Q2 up­date on Wednes­day in­cludes the note that re­searchers have end­ed their Phase II MOON­STONE study, one of a slate of tri­als that Bar­ron has cit­ed to “help es­tab­lish Ze­ju­la as the most com­pelling PARP in­hibitor for women with ovar­i­an can­cer.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.